It would be really baffling if the company were not thinking seriously right now about its finances beyond 2024, and/or talking to potential partners at this time, the latter hopefully being someone who could sign on the dotted line if and when the FDA signalled approval for paediatric aGVHD.
At the very least, If such an approval were forthcoming, the extension/restructuring of the Oaktree loan or its refinancing by some other party should tide the company over to the time when revenue from Ryoncil comes through. There are many other such scenarios that could have equal chances of materialising.
Is this just wild speculation on my part? Perhaps not entirely.
DYOR.
2024 Here we go again., page-441
-
- There are more pages in this discussion • 503 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.023(2.06%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $2.847M | 2.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 23227 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 74933 | 17 |
View Market Depth
| Last trade - 15.05pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |